Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers
Through this acquisition, Ayu Health will add 1000 beds to provide localised primary and tertiary medical care for citizens of Jaipur
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
The recommendation has been sent to the DCGI for approval
The service has already been initiated in Maharashtra but being net-based it is easily available for patients all across the country
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification
Monitoring results demonstrated a good safety profile of the combination. No serious adverse events related to vaccination were registered
Subscribe To Our Newsletter & Stay Updated
